# Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

> **NCT05886660** · PHASE2 · RECRUITING · sponsor: **Repurposed Therapeutics, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Motion Sickness, Space
- Motion Sickness
- Sea Sickness

## Interventions

- **DRUG:** DPI-386 Nasal Gel
- **DRUG:** Placebo Nasal Gel
- **DRUG:** DPI-386 Nasal Gel
- **DRUG:** Placebo Nasal Gel

## Key facts

- **NCT ID:** NCT05886660
- **Lead sponsor:** Repurposed Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886660, "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05886660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*